Tempest Therapeutics, Inc.
Business
Tempest Therapeutics is a clinical-stage biotechnology company developing cell therapy and small molecule candidates for oncology and immunology. Its pipeline includes autologous, allogeneic and in vivo CAR-T therapies targeting multiple antigens in blood cancers and solid tumors, plus two small-molecule programs: amezalpat, a PPARα antagonist in Phase 3-ready development for hepatocellular carcinoma, and TPST-1495, a dual EP2/EP4 antagonist in Phase 2 for familial adenomatous polyposis. The company retains development and commercialization rights to its candidates.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 13 | 28 | 17 | 23 | 17 | |
| General and administrative | 14 | 14 | 12 | 12 | 10 | |
| Operating loss | −27 | −42 | −29 | −35 | −27 | |
| Interest expense | −207,000 | −1 | −1 | — | — | |
| Interest income and other income (expense), net | 520,000 | 1 | 1 | 549,000 | −34,000 | |
| Other income (expense), net | 313,000 | 183,000 | −334,000 | −1 | −1 | |
| Provision for income taxes | 0 | 0 | 0 | 0 | 0 | |
| Net loss | −26 | −42 | −29 | −36 | −28 | |
| Net loss per share of common stock and pre-funded warrants, basic | −6.33 | −19.5 | −1.91 | −3.09 | −7.47 | |
| Net loss per share of common stock and pre-funded warrants, diluted | −6.33 | −19.5 | −1.91 | −3.09 | −7.47 | |
| Weighted-average shares used in computing basic net loss per share | 4 | 2 | 15 | 12 | 4 | |
| Weighted-average shares of common stock and pre-funded warrants outstanding, diluted | 4 | 2 | 15 | 12 | 4 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 8 | 30 | 39 | 31 | 52 | |
| Prepaid expenses and other current assets | 562,000 | 1 | 1 | 1 | 2 | |
| Total current assets | 8 | 31 | 40 | 33 | 69 | |
| Property and equipmentnet | 605,000 | 886,000 | 840,000 | 1 | 1 | |
| Operating lease right-of-use assets | 8 | 9 | 10 | 12 | 3 | |
| Other noncurrent assets | 517,000 | 485,000 | 448,000 | 429,000 | 111,000 | |
| Total assets | 17 | 41 | 52 | 46 | 73 | |
| Accounts payable | 1 | 2 | 845,000 | 1 | 991,000 | |
| Accrued expenses | 937,000 | 3 | 2 | 3 | 2 | |
| Current loan payable (net of discount and issuance costs of nil and $74, respectively) | 0 | 6 | 4 | — | — | |
| Current operating lease liabilities | 1 | 869,000 | 952,000 | 1 | 1 | |
| Accrued compensation | 147,000 | 2 | 2 | 1 | 912,000 | |
| Interest payable | 0 | 59,000 | 113,000 | 97,000 | 92,000 | |
| Total current liabilities | 3 | 14 | 9 | 7 | 20 | |
| Operating lease liabilities, less current portion | 7 | 8 | 9 | 10 | 2 | |
| Total liabilities | 10 | 22 | 25 | 28 | 37 | |
| Commitments and contingencies (Note 5) | — | — | — | — | — | |
| Common stock, $0.001 par value; 100,000,000 shares authorized; 4,927,161 and 3,382,432 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 5,000 | 3,000 | 22,000 | 11,000 | 7,000 | |
| Additional paid-in capital | 240 | 226 | 192 | 154 | 136 | |
| Accumulated deficit | −233 | −207 | −165 | −136 | −100 | |
| Total stockholders' equity | 7 | 19 | 27 | 18 | 36 | |
| Total liabilities and stockholders' equity | 17 | 41 | 52 | 46 | 73 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation expense | 266,000 | 389,000 | 381,000 | 638,000 | 374,000 | |
| Stock-based compensation expense | 3 | 5 | 3 | 2 | 1 | |
| Noncash lease expense | 1 | 1 | 2 | 1 | 896,000 | |
| Noncash interest and other expense, net | 85,000 | 202,000 | 186,000 | 394,000 | 583,000 | |
| Prepaid expenses and other assets | 615,000 | −110,000 | 193,000 | 915,000 | −179,000 | |
| Accounts payable | −1 | 2 | −263,000 | 1,000 | −209,000 | |
| Accrued expenses and other liabilities | −3 | 1 | −992,000 | 2 | 723,000 | |
| Interest payable | −59,000 | −54,000 | 16,000 | −256,000 | 92,000 | |
| Operating lease liabilities | −870,000 | −1 | −2 | −2 | −1 | |
| Cash used in operating activities | −27 | −33 | −27 | −31 | −26 | |
| Purchase of property and equipment | 0 | −435,000 | −170,000 | −562,000 | −135,000 | |
| Cash used in investing activities | 0 | −435,000 | −170,000 | −562,000 | −97,000 | |
| Proceeds from the issuance of common stock, net of issuance costs | 6 | 29 | 36 | 9 | 33 | |
| Proceeds from the issuance of pre-funded warrants, net of issuance costs | 3 | 0 | 0 | 7 | 0 | |
| Proceeds from the issuance of common stock warrants, net of issuance costs | 1 | 0 | — | — | — | |
| Repayment of loan | −6 | −4 | — | −5 | — | |
| Proceeds from the issuance of common stock under equity plan awards | 47,000 | 307,000 | — | — | — | |
| Cash provided by financing activities | 4 | 25 | 36 | 11 | 59 | |
| Net increase in cash and cash equivalents | −23 | −9 | 8 | −20 | 33 | |
| Cash paid for interest | 192,000 | 1 | 1 | 2 | 953,000 | |
| Cash paid for business taxes | 43,000 | 54,000 | 191,000 | 18,000 | — | |
| Property and equipment in accounts payable | 0 | 0 | 0 | 93,000 | 78,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Tempest Therapeutics, Inc.'s CIK number?
Tempest Therapeutics, Inc.'s SEC CIK number is 0001544227 (1544227). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Tempest Therapeutics, Inc.'s SEC filings?
All of Tempest Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Tempest Therapeutics, Inc. last report earnings?
Tempest Therapeutics, Inc. (TPST) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-224156). This is Tempest Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Tempest Therapeutics, Inc.'s most recent earnings 8-K?
Tempest Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001193125-26-224156. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Tempest Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →